Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Cefotaxime sodium 1.048 g equivalent to 1 g cefotaxime; ;
Pfizer New Zealand Limited
Cefotaxime sodium 1.048 g (equivalent to 1 g cefotaxime)
1 g
Powder for injection
Active: Cefotaxime sodium 1.048 g equivalent to 1 g cefotaxime
Vial, glass, single dose, Clear, type III bromobutyl cap, 1 g
Prescription
Prescription
ACS Dobfar SpA
DBL™ Cefotaxime Sodium for Injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. Septicaemia. Respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. Urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. Soft tissue infections: cellulitis, peritonitis and wound infections. Bone and joint infections: osteomyelitis, septic arthritis. Obstetric and gynaecological infections: pelvic inflammatory disease. Gonorrhoea: particularly if penicillin-resistant. Other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. The administration of DBL™ Cefotaxime Sodium for Injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean operations where infections would have serious effects. Protection is best ensured by achieving adequate local tissue concentrations at the time contamination is likely to occur. DBL™ Cefotaxime Sodium for Injection should therefore be administered immediately prior to surgery and if necessary continued in the immediate post-operative period. Administration should usually be stopped within 24 hours since continuing use of any antibiotic in the majority of surgical procedures does not reduce the incidence of subsequent infections.
Package - Contents - Shelf Life: Vial, glass, single dose, Clear, type III bromobutyl cap - 1 g - 36 months unopened stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light - Vial, glass, single dose, Clear, type III bromobutyl cap - 10 dose units - 36 months unopened stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
2000-05-08
Version: pdfcefov11223 Superceded: pdfcefov11020 Page 1 of 15 NEW ZEALAND DATA SHEET 1. PRODUCT NAME DBL™ Cefotaxime Sodium for Injection 1 g Powder for Injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of DBL Cefotaxime Sodium for Injection contains 1 g of cefotaxime sodium. Each gram of DBL Cefotaxime Sodium for Injection contains approximately 48 mg (2.09 mmol) of sodium. For the full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for Injection. DBL Cefotaxime Sodium for Injection is a white to pale yellow crystalline powder. The reconstituted product is a pale yellow solution. Variations in the intensity of colour of the freshly prepared solution do not indicate change in potency or safety. The pH of the formulated material is 4.5 to 6.5. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS DBL Cefotaxime Sodium for Injection is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity: • Septicaemia. • Respiratory tract infections: acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. • Urinary tract infections: acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. • Soft tissue infections: cellulitis, peritonitis and wound infections. • Bone and joint infections: osteomyelitis, septic arthritis. • Obstetric and gynaecological infections: pelvic inflammatory disease. • Gonorrhoea: particularly if penicillin-resistant. • Other bacterial infections: meningitis and other sensitive infections suitable for parenteral antibiotic therapy. • The administration of DBL Cefotaxime Sodium for Injection prophylactically may reduce the incidence of certain post-operative infections in patients undergoing surgical procedures that are classified as contaminated or potentially contaminated or in clean Version: pdfcefov11223 Superceded: pdfcefov11020 Page 2 o Read the complete document